Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis c in an hiv co-infected patient Report as inadecuate




Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis c in an hiv co-infected patient - Download this document for free, or read online. Document in PDF available to download.

Omar Andrés Galdame ; Laura Alicia Barcan ; Adrián Carlos Gadano ;Acta Gastroenterológica Latinoamericana 2015, 45 1

Author: Sebastián Marciano

Source: http://www.redalyc.org/


Teaser



Acta Gastroenterológica Latinoamericana ISSN: 0300-9033 actasage@gmail.com Sociedad Argentina de Gastroenterología Argentina Marciano, Sebastián; Galdame, Omar Andrés; Barcan, Laura Alicia; Gadano, Adrián Carlos Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV coinfected patient Acta Gastroenterológica Latinoamericana, vol.
45, núm.
1, marzo, 2015, pp.
76-79 Sociedad Argentina de Gastroenterología Buenos Aires, Argentina Available in: http:--www.redalyc.org-articulo.oa?id=199336842017 How to cite Complete issue More information about this article Journals homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative ♦CASO CLÍNICO Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient Sebastián Marciano,1 Omar Andrés Galdame,1 Laura Alicia Barcan,2 Adrián Carlos Gadano1 Sección de Hepatología, Sección de Infectología, Hospital Italiano, Buenos Aires, Argentina. 1 2 Acta Gastroenterol Latinoam 2015;45:076-079 Summary Hepatitis C recurrence is the main cause of graft loss in liver transplant patients co-infected with human immunodeficiency virus (HIV).
These patients have higher risk of fibrosing cholestatic hepatitis, which is the most severe type of hepatitis C recurrence.
Until direct antiviral agents were released, only a minority of patients could be satisfactorily treated.
We describe the successful treatment with pegylatedinterferon, ribavirin and telaprevir of an hepatitis C virus (HCV)-HIV co-infected patient who developed fibrosing cholestatic hepatitis after liver transplantation.
A 40-yearold male (HCV genotype 1a; IL-28 CC) underwent liver transplantation for decompensated cirrhosis.
On post-transplant day 60, he rapidly developed progressive jaundice, worsening of liv...





Related documents